Patents Represented by Attorney Sheldon O. Heber
  • Patent number: 8232274
    Abstract: Disclosed is a set of compounds useful as glucan synthase inhibitors having the generic structure of Formula I: wherein the various moieties A, D, R6, etc., are as defined in the specification. These compounds are useful in treating or preventing fungal infections in a patient.
    Type: Grant
    Filed: March 12, 2008
    Date of Patent: July 31, 2012
    Assignees: Albany Molecular Research, Inc., Merck Sharp & Dohme Corp.
    Inventors: Pauline C. Ting, Robert G. Aslanian, Jianhua Cao, David Won-Shik Kim, Rongze Kuang, Gang Zhou, Robert Jason Herr, Andrew John Zych, Jinhai Yang, Heping Wu, Nicolas Zorn
  • Patent number: 8178520
    Abstract: The present invention relates to macrocyclic compounds of formula (I): wherein W, n, R1, Ra, Rb, R3, R4, M, Z, ring A and ring B are defined herein, and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising them, and their use for the treatment or prevention of infection by hepatitis C virus.
    Type: Grant
    Filed: May 11, 2007
    Date of Patent: May 15, 2012
    Assignee: Istituto di Ricerche di Biologia Molecolare P. Angeletti SpA
    Inventors: Maria Emilia Di Francesco, Emanuela Nizi, Paola Pace, Vincenzo Summa
  • Patent number: 8158807
    Abstract: The present invention provides for a process for preparing 6,6-Dimethyl-3-aza-bicyclo[3.1.0]hexane-2-sulfonate, an intermediate useful in the efficient preparation of (1R,2S,5S)-methyl 6,6-dimethyl-3-azabicyclo[3,1,0]hexane-2-carboxylic acid and esters and salts thereof, processes for preparing (1R,2S,5S)-methyl 6,6-dimethyl-3-azabicyclo[3,1,0]hexane-2-carboxylic acid and esters and salts thereof from the sulfonate intermediate and processes for preparing 6,6-Dimethyl-3-aza-bicyclo[3.1.0]hexane-2-sulfonate.
    Type: Grant
    Filed: December 18, 2007
    Date of Patent: April 17, 2012
    Assignee: Schering Corporation
    Inventors: Thierry Berranger, Patrice Demonchaux
  • Patent number: 7989438
    Abstract: A class of macrocyclic compounds of formula (I), wherein R7, A, Ar, B, D, F, M, Q1, Q2, W, X, Y and Z are defined herein, that are useful as inhibitors of viral proteases, particularly the hepatitis C virus (HCV) NS3 protease, are provided. Also provided are processes for the synthesis and use of such macrocyclic compounds for treating or preventing HCV infection.
    Type: Grant
    Filed: July 15, 2008
    Date of Patent: August 2, 2011
    Assignee: Istituto di Ricerche di Biologia Molecolare P. Angeletti SpA
    Inventors: Immacolata Conte, Joerg Habermann, Angela Mackay, Frank Narjes, Maria del Rosario Rico Ferreira, Ian Stansfield
  • Patent number: 7879797
    Abstract: The present invention relates to macrocyclic compounds of formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections.
    Type: Grant
    Filed: April 28, 2006
    Date of Patent: February 1, 2011
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: M. Katharine Holloway, Nigel J. Liverton, Steven W. Ludmerer, John A. McCauley, David Olsen, Michael T. Rudd, Joseph P. Vacca
  • Patent number: 7795250
    Abstract: The present invention relates to indole compounds of the formula (I): wherein R1, R2, R3, R4, A, E and X are as defined herein, and pharmaceutically acceptable salts thereof, useful in the prevention and treatment of hepatitis C infections.
    Type: Grant
    Filed: June 8, 2005
    Date of Patent: September 14, 2010
    Assignee: Istituto di Ricerche di Biologia Molecolare P Angeletti SpA
    Inventors: Stefania Colarusso, Immacolata Conte, Joerg Habermann, Frank Narjes, Simona Ponzi
  • Patent number: 7611868
    Abstract: Recombinant adenoviruses comprising modified fiber proteins which expand the tropism of the adenovirus in comparison to wild-type virus are disclosed. The modified fiber proteins described herein contain a peptide ligand for a cell surface binding site other than CAR comprising a 14 amino acid core sequence containing both fixed and variable amino acid residues. The invention includes isolated nucleic acid molecules encoding the modified adenovirus fiber proteins disclosed, as well as recombinant vectors and host cells containing said nucleic acid molecules. Methods of identifying peptide ligands that bind to cell binding sites other than CAR are included comprising screening a phage-display library of peptide ligands expressed within an adenovirus fiber knob context on CAR-negative cells.
    Type: Grant
    Filed: May 10, 2004
    Date of Patent: November 3, 2009
    Assignee: Instituto di Ricerche di Biologia Molecolare P. Angeletti S.p.A.
    Inventors: Paolo Monaci, Laura Fontana
  • Patent number: 7598362
    Abstract: The present invention features Ad6 vectors and a nucleic acid encoding a Met-NS3-NS4A-NS4B-NS5A-NS5B polypeptide containing an inactive NS5B RNA-dependent RNA polymerase region. The nucleic acid is particularly useful as a component of an adenovector or DNA plasmid vaccine providing a broad range of antigens for generating an HCV specific cell mediated immune (CMI) response against HCV.
    Type: Grant
    Filed: October 10, 2002
    Date of Patent: October 6, 2009
    Assignees: Merck & Co., Inc., Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.p.A.
    Inventors: Emilio A. Emini, David C. Kaslow, Andrew J. Bett, John W. Shiver, Alfredo Nicosia, Armin Lahm, Alessandra Luzzago, Riccardo Cortese, Stefano Colloca
  • Patent number: 7208282
    Abstract: The present invention identifies the presence of MCH-2R in the dog, ferret and rhesus monkey. MCH-2R is a G-protein coupled receptor that responds to MCH and is distinct from MCH-1R. MCH-2R polypeptide and nucleic acid sequences related to the dog, ferret, and rhesus monkey MCH-2R are described herein along with uses of such polypeptides and nucleic acids.
    Type: Grant
    Filed: May 28, 2002
    Date of Patent: April 24, 2007
    Assignees: Merck & Co., Inc., Banyu Pharmaceutical Co., Ltd.
    Inventors: Carina Tan, Hideki Sano
  • Patent number: 7198910
    Abstract: The present application features two different forms of the human MCH receptor: (1) MCH-R2 and (2) MCH-R3. Such MCH receptors provide a target for achieving a beneficial affect in a patient and facilitate the screening of compounds that modulate MCH receptor activity or expression. Beneficial effects that can be obtained include increasing appetite, decreasing appetite, and reducing stress.
    Type: Grant
    Filed: July 10, 2000
    Date of Patent: April 3, 2007
    Assignee: Merck & Co., Inc.
    Inventor: Andrew D. Howard
  • Patent number: 7078215
    Abstract: Truncated HCV NS2/3 can be produced recombinantly and renatured into functional enzyme, useful in assays for modulators of activity and HCV function.
    Type: Grant
    Filed: March 14, 2001
    Date of Patent: July 18, 2006
    Assignee: Istituto Di Ricerche Di Biologia Molecolare P. Angeletti, S.P.A.
    Inventors: Christian Steinkuhler, Michele Pallaoro, Armin Lahm
  • Patent number: 7034108
    Abstract: Peptides which are mimotopes of the hypervariable region 1 (HVR1) of the putative envelope protein E2 of hepatitis C virus (HCV) are provided, useful in obtaining antibodies and raising an immune response cross-reactive against different strains of HCV.
    Type: Grant
    Filed: May 14, 1999
    Date of Patent: April 25, 2006
    Assignee: Istituto di Ricerche di Biologia Molecolare P. Angeletti S.p.A.
    Inventors: Alfredo Nicosia, Armin Lahm, Anna Tramontano, Riccardo Cortese
  • Patent number: 7029878
    Abstract: The present invention features melanin concentrating hormone receptor (MCH-R) chimeric and fusion proteins. MCH-R chimeric proteins comprise an MCH-R polypeptide region made up of at least two or more polypeptide regions characteristic of MCH-R found in different species. MCH-R fusion proteins comprise an MCH-R polypeptide region and a fluorescent protein region.
    Type: Grant
    Filed: March 14, 2001
    Date of Patent: April 18, 2006
    Assignee: Merck & Co., Inc.
    Inventor: Donald J. Marsh
  • Patent number: 7015008
    Abstract: The present invention features antibodies referred to herein as “MAb50-4” and “MAb184-10”, and polypeptides that compete with MAb50-4 and MAb184-10 for binding to CYP2D6. MAb50-4 can be produced by ATCC No. PTA-3489, while MAb184-10 can be produced by ATCC No. PTA-1999.
    Type: Grant
    Filed: September 25, 2001
    Date of Patent: March 21, 2006
    Assignee: Merck & Co., Inc.
    Inventors: Magang Shou, Qin Mei
  • Patent number: 6967237
    Abstract: The present invention features truncated ghrelin analogs active at the GHS receptor. Ghrelin is a naturally occurring modified peptide. The analogs can bind to the GHS receptor and, preferably, bring about signal transduction. Ghrelin analogs have a variety of different uses including being used as a research tool and being used therapeutically.
    Type: Grant
    Filed: May 25, 2001
    Date of Patent: November 22, 2005
    Assignee: Merck & Co., Inc.
    Inventor: Maria A. Bednarek
  • Patent number: 6960558
    Abstract: The present invention relates to methods for screening for anti-obesity agents using the ciliary neutrophic factor receptor.
    Type: Grant
    Filed: January 31, 2003
    Date of Patent: November 1, 2005
    Assignee: Instituto di Recerche di Biologia Molecolare P. Angeletti S.p.A.
    Inventors: Gennaro Ciliberto, Isabelle Gloaguen, Annalise Di Marco, Anna Demartis, Ralph Laufer, Riccardo Cortese
  • Patent number: 6955891
    Abstract: The present invention features a Bacillus anthracis lethal factor substrate. The substrate can be used for example to measure lethal factor activity. Preferred substrates contain one or mare detectable labels and have a sufficiently high turnover rate for applications in a high throughput screen.
    Type: Grant
    Filed: April 28, 2003
    Date of Patent: October 18, 2005
    Assignee: Merck & Co., Inc.
    Inventors: Barry R. Cunningham, Richard T. Cummings, Jeffrey D. Hermes, Scott Salowe
  • Patent number: 6906320
    Abstract: The present invention features mass spectrometry data analysis techniques that can be employed to selectively identify analytes differing in abundance between different sample sets. The employed techniques determine the statistical significance of changes to signals associated with mass-to-charge ratios (“m/z-intensity pairs”) between individual samples and sample sets. Based on the statistical significance, changes likely to indicate analyte level differences are identified. Based on intensities of the signals, ratios of analyte abundances can be determined.
    Type: Grant
    Filed: March 31, 2004
    Date of Patent: June 14, 2005
    Assignee: Merck & Co., Inc.
    Inventors: Jeffrey R. Sachs, Matthew C. Wiener, Nathan A. Yates
  • Patent number: 6867284
    Abstract: Fluorinated oligopeptides, especially those having 4,4-difluoro-2-amino butyric acid at the C terminus, may be effective inhibitors of hepatitis C virus NS3 protease. Examples of hexapeptides of the invention, optimized for binding in the S1 specificity pocket of the enzyme, may display IC50s at the sub-micromolar level. Embodiments of tripeptides of the invention, having a keto-acid group at the C-terminus are, likewise, potent inhibitors of NS3 protease.
    Type: Grant
    Filed: June 9, 1999
    Date of Patent: March 15, 2005
    Assignee: Istituto di Ricerche di Biologia Molecolare P. Angeletti S.p.A.
    Inventors: Victor Matassa, Frank Narjes, Konrad Forster Koehler, Jesus Ontoria, Marco Poma, Antonella Marchetti
  • Patent number: RE43298
    Abstract: The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.
    Type: Grant
    Filed: April 22, 2011
    Date of Patent: April 3, 2012
    Assignees: Schering Corporation, Dendreon Corporation
    Inventors: Anil K. Saksena, Viyyoor Moopil Girijavallabhan, Raymond G. Lovey, Edwin Jao, Frank Bennett, Jinping L. McCormick, Haiyan Wang, Russell E. Pike, Stephane L. Bogen, Tin-Yau Chan, Yi-Tsung Liu, Zhaoning Zhu, F. George Njoroge, Ashok Arasappan, Tejal Parekh, Ashit K. Ganguly, Kevin X. Chen, Srikanth Venkatraman, Henry M. Vaccaro, Patrick A. Pinto, Bama Santhanam, Scott Jeffrey Kemp, Odile Esther Levy, Marguerita Lim-Wilby, Susan Y. Tamura, Wanli Wu, Siska Hendrata, Yuhua Huang